Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandospirone vs Shuganjieyu capsule for comorbid anxiety and depression in epilepsy
ChiCTR2100046582Phase 4Completed
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of tandospirone and Shugan Jieyu in epilepsy, major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Frequency of seizures, Depression and anxiety and 2 more. Started Jan 2018; status: completed.
02
Drugs
tandospironeShugan Jieyu
03
Conditions
epilepsymajor depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2100046582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046582.